Standard Therapy Prevails in Head & Neck Cancer Trial

(MedPage Today) — Neither a single immune checkpoint inhibitor nor a combination improved survival versus standard of care for patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC), an international randomized trial…
Read More

Leave a Reply

%d bloggers like this: